Literature DB >> 18288081

Risk sharing and payment by results.

A Breckenridge, T Walley.   

Abstract

Mesh：

Year:  2008        PMID： 18288081     DOI： 10.1038/clpt.2008.15

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  7 in total

1.  Drugs, money and society (Part II).

Authors:  Tom Walley
Journal:  Br J Clin Pharmacol       Date:  2010-09       Impact factor: 4.335

2.  Access with evidence development schemes: a framework for description and evaluation.

Authors:  Christopher J McCabe; Tania Stafinski; Richard Edlin; Devidas Menon
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 3.  The Use of Risk-Sharing Contracts in Healthcare: Theoretical and Empirical Assessments.

Authors:  Fernando Antonanzas; Carmelo Juárez-Castelló; Reyes Lorente; Roberto Rodríguez-Ibeas
Journal:  Pharmacoeconomics       Date:  2019-12       Impact factor: 4.981

4.  Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong?

Authors:  Adrian Towse
Journal:  Br J Clin Pharmacol       Date:  2010-09       Impact factor: 4.335

Review 5.  Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems.

Authors:  Tania Stafinski; Christopher J McCabe; Devidas Menon
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 6.  Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.

Authors:  Jakub Adamski; Brian Godman; Gabriella Ofierska-Sujkowska; Bogusława Osińska; Harald Herholz; Kamila Wendykowska; Ott Laius; Saira Jan; Catherine Sermet; Corrine Zara; Marija Kalaba; Roland Gustafsson; Kristina Garuolienè; Alan Haycox; Silvio Garattini; Lars L Gustafsson
Journal:  BMC Health Serv Res       Date:  2010-06-07       Impact factor: 2.655

7.  The use of risk sharing tools for post adoption surveillance of a non pharmacological technology in routine practice: results after one year.

Authors:  Carlos Campillo-Artero; Francisco M Kovacs
Journal:  BMC Health Serv Res       Date:  2013-05-20       Impact factor: 2.655
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.